Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Oxyquinoline→

Oxyquinoline Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
148-24-3
Molecular formula
C9H7NO
Molecular weight
145.16 g/mol
Drug class
8-Hydroxyquinoline antisepticlocal antimicrobial and metal-chelating agent
Mechanism of action
A hydroxyquinoline compound with local antimicrobial activity. Its actions are associated with chelation of essential metal ions and interference with microbial enzymes and cellular processes; the exact contribution of each mechanism varies by organism and formulation.
Indications / reported uses
  • Historical or formulation-specific local antiseptic use in topical, oral or vaginal preparations where oxyquinoline-containing products are authorised.

Sources: https://www.ncbi.nlm.nih.gov/mesh/?term=oxyquinoline · https://pubchem.ncbi.nlm.nih.gov/#query=oxyquinoline · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Oxyquinoline Environmental Risk Assessment (ERA) (the Oxyquinoline ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.